Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections

Chun Kai Huang, Yao Shen Chen, Susan Shin Jung Lee, Wei Ru Lin, Hung Chin Tsai, Hsi Hsun Lin, Shue Ren Wann, Joanna Yan Wan Chen, Muh Yong Yen, Yung Ching Liu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

An open-label, randomized study was conducted to evaluate the safety and efficacy of cefepime versus ceftazidime in the treatment of severe bacterial infections, including septicemia, urinary tract infection, bacterial bronchitis, bacterial pneumonia, and intraabdominal infection. Fifty-two patients with severe infections were eligible and prospectively randomized to receive cefepime (26 patients) or ceftazidime (26 patients) during a 15-month period. Forty-two patients were evaluable (24 in the cefepime group and 18 in the ceftazidime group). Most (86%) of the patients had urinary tract infections and the most commonly isolated pathogen was Escherichia coli (79%). Satisfactory clinical response rates of 71% and 61%, and bacteriological eradication rates of 87.5% and 89% were achieved for the cefepime and ceftazidime groups, respectively. Two patients treated with cefepime died, one from superinfection and one from suspected paraneoplastic syndrome. Cultures of the blood obtained at entry into the study were positive in 19 (45%) of the 42 evaluable cases. In the cefepime group, a patient with Salmonella paratyphi A septicemia was cured, which has not been previously reported. Adverse effects attributable to therapy were minimal in both groups of patients, and none required discontinuation or dose reduction. In conclusion, these results suggest that cefepime is as efficacious and well tolerated as ceftazidime in the treatment of severe bacterial infections, such as septicemia, urinary tract infection, bacterial bronchitis, bacterial pneumonia, and intraabdominal infection.

Original languageEnglish
Pages (from-to)159-167
Number of pages9
JournalJournal of Microbiology, Immunology and Infection
Volume35
Issue number3
Publication statusPublished - Sep 2002
Externally publishedYes

Fingerprint

Ceftazidime
Safety
Infection
Bacterial Infections
Urinary Tract Infections
Intraabdominal Infections
Bacterial Pneumonia
Sepsis
Bronchitis
Therapeutics
Salmonella paratyphi A
Paraneoplastic Syndromes
Superinfection
cefepime
Escherichia coli

Keywords

  • Cefepime
  • Ceftazidime
  • Severe bacterial infections

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Allergy
  • Immunology and Microbiology(all)

Cite this

Huang, C. K., Chen, Y. S., Lee, S. S. J., Lin, W. R., Tsai, H. C., Lin, H. H., ... Liu, Y. C. (2002). Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections. Journal of Microbiology, Immunology and Infection, 35(3), 159-167.

Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections. / Huang, Chun Kai; Chen, Yao Shen; Lee, Susan Shin Jung; Lin, Wei Ru; Tsai, Hung Chin; Lin, Hsi Hsun; Wann, Shue Ren; Chen, Joanna Yan Wan; Yen, Muh Yong; Liu, Yung Ching.

In: Journal of Microbiology, Immunology and Infection, Vol. 35, No. 3, 09.2002, p. 159-167.

Research output: Contribution to journalArticle

Huang, CK, Chen, YS, Lee, SSJ, Lin, WR, Tsai, HC, Lin, HH, Wann, SR, Chen, JYW, Yen, MY & Liu, YC 2002, 'Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections', Journal of Microbiology, Immunology and Infection, vol. 35, no. 3, pp. 159-167.
Huang, Chun Kai ; Chen, Yao Shen ; Lee, Susan Shin Jung ; Lin, Wei Ru ; Tsai, Hung Chin ; Lin, Hsi Hsun ; Wann, Shue Ren ; Chen, Joanna Yan Wan ; Yen, Muh Yong ; Liu, Yung Ching. / Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections. In: Journal of Microbiology, Immunology and Infection. 2002 ; Vol. 35, No. 3. pp. 159-167.
@article{cf74dba4c0d2426b9edc17ddb38d294f,
title = "Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections",
abstract = "An open-label, randomized study was conducted to evaluate the safety and efficacy of cefepime versus ceftazidime in the treatment of severe bacterial infections, including septicemia, urinary tract infection, bacterial bronchitis, bacterial pneumonia, and intraabdominal infection. Fifty-two patients with severe infections were eligible and prospectively randomized to receive cefepime (26 patients) or ceftazidime (26 patients) during a 15-month period. Forty-two patients were evaluable (24 in the cefepime group and 18 in the ceftazidime group). Most (86{\%}) of the patients had urinary tract infections and the most commonly isolated pathogen was Escherichia coli (79{\%}). Satisfactory clinical response rates of 71{\%} and 61{\%}, and bacteriological eradication rates of 87.5{\%} and 89{\%} were achieved for the cefepime and ceftazidime groups, respectively. Two patients treated with cefepime died, one from superinfection and one from suspected paraneoplastic syndrome. Cultures of the blood obtained at entry into the study were positive in 19 (45{\%}) of the 42 evaluable cases. In the cefepime group, a patient with Salmonella paratyphi A septicemia was cured, which has not been previously reported. Adverse effects attributable to therapy were minimal in both groups of patients, and none required discontinuation or dose reduction. In conclusion, these results suggest that cefepime is as efficacious and well tolerated as ceftazidime in the treatment of severe bacterial infections, such as septicemia, urinary tract infection, bacterial bronchitis, bacterial pneumonia, and intraabdominal infection.",
keywords = "Cefepime, Ceftazidime, Severe bacterial infections",
author = "Huang, {Chun Kai} and Chen, {Yao Shen} and Lee, {Susan Shin Jung} and Lin, {Wei Ru} and Tsai, {Hung Chin} and Lin, {Hsi Hsun} and Wann, {Shue Ren} and Chen, {Joanna Yan Wan} and Yen, {Muh Yong} and Liu, {Yung Ching}",
year = "2002",
month = "9",
language = "English",
volume = "35",
pages = "159--167",
journal = "Journal of Microbiology, Immunology and Infection",
issn = "0253-2662",
publisher = "Elsevier Taiwan LLC",
number = "3",

}

TY - JOUR

T1 - Safety and efficacy of cefepime versus ceftazidime in the treatment of severe infections

AU - Huang, Chun Kai

AU - Chen, Yao Shen

AU - Lee, Susan Shin Jung

AU - Lin, Wei Ru

AU - Tsai, Hung Chin

AU - Lin, Hsi Hsun

AU - Wann, Shue Ren

AU - Chen, Joanna Yan Wan

AU - Yen, Muh Yong

AU - Liu, Yung Ching

PY - 2002/9

Y1 - 2002/9

N2 - An open-label, randomized study was conducted to evaluate the safety and efficacy of cefepime versus ceftazidime in the treatment of severe bacterial infections, including septicemia, urinary tract infection, bacterial bronchitis, bacterial pneumonia, and intraabdominal infection. Fifty-two patients with severe infections were eligible and prospectively randomized to receive cefepime (26 patients) or ceftazidime (26 patients) during a 15-month period. Forty-two patients were evaluable (24 in the cefepime group and 18 in the ceftazidime group). Most (86%) of the patients had urinary tract infections and the most commonly isolated pathogen was Escherichia coli (79%). Satisfactory clinical response rates of 71% and 61%, and bacteriological eradication rates of 87.5% and 89% were achieved for the cefepime and ceftazidime groups, respectively. Two patients treated with cefepime died, one from superinfection and one from suspected paraneoplastic syndrome. Cultures of the blood obtained at entry into the study were positive in 19 (45%) of the 42 evaluable cases. In the cefepime group, a patient with Salmonella paratyphi A septicemia was cured, which has not been previously reported. Adverse effects attributable to therapy were minimal in both groups of patients, and none required discontinuation or dose reduction. In conclusion, these results suggest that cefepime is as efficacious and well tolerated as ceftazidime in the treatment of severe bacterial infections, such as septicemia, urinary tract infection, bacterial bronchitis, bacterial pneumonia, and intraabdominal infection.

AB - An open-label, randomized study was conducted to evaluate the safety and efficacy of cefepime versus ceftazidime in the treatment of severe bacterial infections, including septicemia, urinary tract infection, bacterial bronchitis, bacterial pneumonia, and intraabdominal infection. Fifty-two patients with severe infections were eligible and prospectively randomized to receive cefepime (26 patients) or ceftazidime (26 patients) during a 15-month period. Forty-two patients were evaluable (24 in the cefepime group and 18 in the ceftazidime group). Most (86%) of the patients had urinary tract infections and the most commonly isolated pathogen was Escherichia coli (79%). Satisfactory clinical response rates of 71% and 61%, and bacteriological eradication rates of 87.5% and 89% were achieved for the cefepime and ceftazidime groups, respectively. Two patients treated with cefepime died, one from superinfection and one from suspected paraneoplastic syndrome. Cultures of the blood obtained at entry into the study were positive in 19 (45%) of the 42 evaluable cases. In the cefepime group, a patient with Salmonella paratyphi A septicemia was cured, which has not been previously reported. Adverse effects attributable to therapy were minimal in both groups of patients, and none required discontinuation or dose reduction. In conclusion, these results suggest that cefepime is as efficacious and well tolerated as ceftazidime in the treatment of severe bacterial infections, such as septicemia, urinary tract infection, bacterial bronchitis, bacterial pneumonia, and intraabdominal infection.

KW - Cefepime

KW - Ceftazidime

KW - Severe bacterial infections

UR - http://www.scopus.com/inward/record.url?scp=0036744158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036744158&partnerID=8YFLogxK

M3 - Article

C2 - 12380788

AN - SCOPUS:0036744158

VL - 35

SP - 159

EP - 167

JO - Journal of Microbiology, Immunology and Infection

JF - Journal of Microbiology, Immunology and Infection

SN - 0253-2662

IS - 3

ER -